Anti Vascular Endothelial Growth Factor Agents in Corneal Neovascularization
Corneal neovascularisation is a potentially blinding condition, an established risk factor for rejection and results in loss of immune privilege. It may occur as a normal physiologic healing response to various stimuli or as an inappropriate local tissue response to primary insult arising due to an...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2011-07-01
|
| Series: | Delhi Journal of Ophthalmology |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/0972-0200.376568 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Corneal neovascularisation is a potentially blinding condition, an established risk factor for rejection and results in loss of immune privilege. It may occur as a normal physiologic healing response to various stimuli or as an inappropriate local tissue response to primary insult arising due to an imbalance between the angiogenic and antiangiogenic factors present in the normally avascular cornea. Medical and surgical treatment modalities have been described for the condition but there is no established treatment protocol. Anti vascular endothelial growth factor (Anti VEGF) agents are increasingly being used for the condition. In this article, we have presented the pathogenesis of corneal neovascularisation, role of VEGF and discussed the emerging use of anti VEGF agents as a treatment modality. |
|---|---|
| ISSN: | 0972-0200 2454-2784 |